![Scott N. Cullison](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Scott N. Cullison
Corporate Officer/Principal bei XENETIC BIOSCIENCES, INC.
Aktive Positionen von Scott N. Cullison
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
XENETIC BIOSCIENCES, INC. | Corporate Officer/Principal | - | - |
Karriereverlauf von Scott N. Cullison
Ehemalige bekannte Positionen von Scott N. Cullison
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BELLICUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.08.2015 | 01.11.2018 |
PELOTON THERAPEUTICS, INC. | Corporate Officer/Principal | - | - |
Targacept, Inc.
![]() Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | Corporate Officer/Principal | 26.10.2010 | - |
Ausbildung von Scott N. Cullison
Wake Forest University | Masters Business Admin |
University of Arizona | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Operativ
Corporate Officer/Principal | 4 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
XENETIC BIOSCIENCES, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Targacept, Inc.
![]() Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | Health Technology |
Bellicum Pharmaceuticals, Inc.
![]() Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Peloton Therapeutics, Inc.
![]() Peloton Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX. | Health Technology |
- Börse
- Insiders
- Scott N. Cullison
- Erfahrung